{'fraction_non_alphanumeric': 0.023605150214592276, 'fraction_numerical': 0.02145922746781116, 'mean_word_length': 5.397260273972603, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of cotrimoxazole prophylaxis on malaria occurrence among HIV‐infected adults in West Africa: the MALHIV Study

Cotrimoxazole (CTX) should be given to all HIV‐infected adults with mild or severe HIV‐disease or those with CD4 counts below 350/mm3 according to 2006 WHO guidelines. We assessed the impact of CTX prophylaxis on the risk of malaria episodes in HIV‐1‐infected adults from four West African countries with different patterns of malaria transmission.